Insurance companies are proposing a double-digit rate hike in 2016, with Blue Cross Blue Shield seeking a premium increase of 20% or more in several states.
Citing unexpected healthcare costs in 2015, several insurance companies are proposing a double-digit rate hike in 2016, with Blue Cross Blue Shield seeking a premium increase of 20% or more in several states. The Affordable Care Act and expensive specialty medications that have recently entered the market are 2 of several reasons for this proposed hike, according to insurance companies. The steep increase in premium would affect plans sold on the state-run health insurance exchanges as well as individual coverage sold through brokers and agents. State health regulators can reject the steep rises or can pressure insurance companies to reduce the rate of increase.
Some insurers may be seeking what seems like a sizeable rate increase because they charged much less than the competition for this year, according to Catherine Murphy-Barron, vice president of health with the American Academy of Actuaries.
Read more at Yahoo!Finance: http://yhoo.it/1Q4er2E
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More
2 Commerce Drive
Cranbury, NJ 08512